Key result
Black-market GLP-1 drugs retatrutide and zenagamtide carry substantial potential clinical risks.
This medical news article highlights the growing black market and potential safety risks associated with online sales of the unapproved GLP-1 weight loss drugs retatrutide and zenagamtide.
Answers are grounded in this paper and cite their sources.
Clinicians should caution patients against online unapproved GLP-1 agonists; leaves open systematic safety profiling of black-market formulations.
This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.
No takes yet. Share an insight, caveat, or question.
Rita Rubin (2026) studied this question. Unapproved GLP-1 weight loss drugs retatrutide and zenagamtide sold on the online black market carry potential clinical risks.
Synapse has enriched 10 related papers. Consider them for comparative context: